A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis
Adam Schiffenbauer(National Institute of Environmental Health Sciences), Mark F. Gourley(National Institutes of Health), Joseph A. Shrader(National Institutes of Health Clinical Center), Christine Castro(National Institutes of Health), Frederick W. Miller(National Institutes of Health), Sara Faghihi‐Kashani(National Institute of Environmental Health Sciences), Paul H. Plötz(National Institutes of Health), Michael O. Harris‐Love(National Institutes of Health), Megha Garg(National Centre for Biological Sciences), Angelina Pokrovnichka(National Institutes of Health), Galen O. Joe(National Institutes of Health Clinical Center), Imelda Cabalar(National Institutes of Health)
Cited by 70
Related Papers
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
|Proceedings of the National Academy of Sciences|2007|598
Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus Erythematosus
|New England Journal of Medicine|1979|531
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
|The Journal of Experimental Medicine|2005|395